SUGGESTED FORMULA

Chlorambucil 4mg/mL Suspension – Oil Formula

Version number: 1.0

Volume: 50 mL

Chlorambucil, USP (C1659)	0.2gm
Flavor, Powder	0.5 gm, OR
Flavor, Oil Soluble	2.5 mL
Corn Oil, NF (CO136)	50mL Q.S.

*If using a powder flavor, add powder to step#2 and dry triturate with Chlorambucil. If using a liquid flavor add directly to the bottle

SUGGESTED COMPOUNDING PROCEDURES

1. Weigh Chlorambucil and place in mortar and pestle
2. Dry triturate to break down any clumps in the chemical
3. Add enough oil into mortar and pestle to form a "paste"
4. Triturate until all Chlorambucil is broken down and incorporated into liquid
5. Add more oil until pourable mixture and pour into calibrated final container
6 Perform liquid "washes" in mortar and pestle to integrate remaining chemical
7. Pour each "wash" into final container taking precaution not to go over the final volume
8. Q.S. medication and shake well.
8. Suggested Quality Assessments – follow pharmacy SOPs:
   a. Weight to Volume calculation
   b. Color
   c. Pourability
   d. Settling
   e. Resuspendability

***Pregnant women should not handle this medication**
***Cytotoxic Agent-Dispose properly**
***Keep out of the reach of children**

Store in air tight amber plastic containers

Store Room Temperature

No claims are made as to the safety or efficacy of this preparation. This formulation is provided solely at the unsolicited request of the pharmacist.

Beyond-Use Dates of preparations are conservative estimates by the formulator using reference books, peer-reviewed literature, and intended duration of therapy, formulation from commercially available products, organoleptic observations and current USP guidelines. Compounders may have stability studies performed by a reputable laboratory if they wish to extend the Beyond-Use Date.
It is recommended that you follow USP <795> recommendations for potency testing.

Beyond-Use Date should be based on the current version of USP <795>.

****Precautions**

Hazardous drugs should be handled according to USP <800>, NIOSH standards and pharmacy SOPs. This preparation should be compounded in a USP <800> compliant containment ventilated enclosure (CVE). Precautions should be taken to prevent cross-contamination and exposure of ingredients to the compounder and contamination of the preparation by the compounder. Wear appropriate personal protective equipment (PPE).

11/18 JD

Phone: 800.370.6231 | Fax: 732.608.5420 | Internet: SpectrumRx.com | Email: sales@spectrumrx.com